What is NDC 84141-025?

84141-025 is the product NDC for Redemplo (plozasiran), Plozasiran 25 mg/.5mL injection, solution, listed with the FDA by Arrowhead Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Arrowhead Pharmaceuticals, Inc., NDC labeler code 84141. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Redemplo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Redemplo NDC 84141-025 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)84141-025Labeler and product segments. Claims need a package NDC.

Product NDC at billing width84141-0025Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
84141-025-01	84141002501	1 SYRINGE, GLASS in 1 CARTON (84141-025-01) / 1 mL in 1 SYRINGE, GLASSMarketed from Nov 19, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Redemplo
Generic name (nonproprietary): plozasiran
Active ingredients: Plozasiran — 25 mg/.5mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Arrowhead Pharmaceuticals, Inc.NDC labeler code 84141
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 219947
Marketing start: Nov 19, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Increased RNA Degradation (Physiologic effect)Small Interfering (Chemical structure)
Identifiers: Product ID 84141-025_4b987e0d-345d-4ba3-b5d6-d70c1bfe0fd7SPL ID 4b987e0d-345d-4ba3-b5d6-d70c1bfe0fd7SPL set ID 7fd37993-f85a-4af1-8bbe-133299f226edRxCUI 2728183, 2728184UNII XG9ARL6P25
Pharmacologic class: APOC-III-directed RNA Interaction; Small Interfering RNA

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N484141002501 followed by a unit qualifier and the quantity

Package 84141-0025-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 25, 2026.

Indications (excerpt from the label)

REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is an apolipoprotein C-III ( apoC-III )-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 84141-025

What is NDC 84141-025?: 84141-025 is the product NDC for Redemplo (plozasiran), Plozasiran 25 mg/.5mL injection, solution, listed with the FDA by Arrowhead Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Redemplo (Plozasiran).
What is the active ingredient?: Plozasiran.
Who is the labeler?: Arrowhead Pharmaceuticals, Inc., NDC labeler code 84141. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Redemplo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Redemplo (Plozasiran) NDC 84141-025